Who is sponsoring NCT00038493?

NCT00038493 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00038493?

Interventions in NCT00038493: Temozolomide and SCH66336.

What condition does NCT00038493 study?

NCT00038493 studies Glioblastoma Multiforme.

Is NCT00038493 still recruiting?

NCT00038493 is currently completed. Last updated 29 October 2018.

Last reviewed 2018-10-29 · How we verify

NCT00038493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme

Completed Phase 2 Last updated 29 October 2018

What this trial tests

Phase 2 trial testing Temozolomide and SCH66336 in Glioblastoma Multiforme in 23 participants. Completed in 1 August 2005.

Timeline

21 September 2001

Primary endpoint
1 August 2005

1 August 2005

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	21 September 2001
Primary completion	1 August 2005
Estimated completion	1 August 2005
Sites	1 location across United States

Drugs / interventions tested

Temozolomide and SCH66336 — full drug profile →

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth). Patients will be treated with oral temozolomide on days 1-5 and oral SCH66336 on days 8-28 every 28 days.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment.
Li W, Li F, Zhang X, Lin HK, et al · · 2021 · cited 147× · PMID 34924561 · DOI 10.1038/s41392-021-00825-8
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication.
Yuan Y, Li P, Li J, Zhao Q, et al · · 2024 · cited 56× · PMID 38485938 · DOI 10.1038/s41392-024-01759-7
Therapeutic Options in Neuro-Oncology.
Afonso M, Brito MA. · · 2022 · cited 13× · PMID 35628161 · DOI 10.3390/ijms23105351
Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas.
Giotta Lucifero A, Luzzi S, Brambilla I, Schena L, et al · · 2020 · cited 12× · PMID 32608376 · DOI 10.23750/abm.v91i7-s.9956
Epigenomic and Metabolic Interplay in the Development of Metastatic Brain Tumors.
Rastogi V, Verma D, Verma S, Haloi P, et al · · 2026 · PMID 41799524 · DOI 10.32604/or.2026.072620

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00038493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 29 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00038493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing